Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux.
To assess the response to and tolerance of recombinant interferon-alpha administration in patients with chronic hepatitis C and human immunodeficiency virus (HIV) infection, 12 patients with chronic hepatitis C and HIV infection were given interferon-alpha, 1, 3, or 5 million units thrice weekly, for 4 or 6 months. Four patients had a complete response (normal serum alanine aminotransferase activity [ALT]), 3 had a near-complete response (serum ALT less than one-and-one-half times the upper limit of normal), and 5 had no response at the end of administration. Histologic examination of liver showed an improvement in 1 patient with complete response and no improvement in another patient with no response. In patients with chronic hepatitis C with HIV infection, the response to and tolerance of recombinant interferon-alpha were not different from those usually observed in patients with chronic hepatitis C infection without HIV infection.
Boyer
N
N
Service d'Hépatologie, Hôpital Beaujon, Clichy, France.
Marcellin
P
P
Degott
C
C
Degos
F
F
Saimot
A G
AG
Erlinger
S
S
Benhamou
J P
JP
D000328:Adult; D015496:CD4-Positive T-Lymphocytes; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000150:complications / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007958:Leukocyte Count; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D016896:Treatment Outcome
D007370:Interferon Type I; D011994:Recombinant Proteins